POLARAMINE Drug Patent Profile

When do Polaramine patents expire, and when can generic versions of Polaramine launch?

Polaramine is a drug marketed by Schering and is included in two NDAs.

The generic ingredient in POLARAMINE is dexchlorpheniramine maleate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexchlorpheniramine maleate profile page.

Summary for POLARAMINE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	1
Patent Applications:	5,300
DailyMed Link:	POLARAMINE at DailyMed

Recent Clinical Trials for POLARAMINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Bordeaux	Phase 3

See all POLARAMINE clinical trials

US Patents and Regulatory Information for POLARAMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	POLARAMINE	dexchlorpheniramine maleate	SYRUP;ORAL	086837-001	Jul 19, 1982		DISCN	No	No
Schering	POLARAMINE	dexchlorpheniramine maleate	TABLET;ORAL	086835-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Polaramine Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: August 7, 2026

Polaramine is a mature antihistamine brand based on dexchlorpheniramine maleate. Its commercial profile is defined by generic competition, low regulatory barriers, limited pricing power, and fragmented geographic ownership. No reliable public source reports standalone global Polaramine revenue. The product has no identifiable active patent moat in the major markets reviewed, and its economic value is concentrated in local brand recognition, distribution, and regulatory registrations rather than exclusivity.

What is Polaramine and how does it work?

Polaramine contains dexchlorpheniramine maleate, a first-generation H1 antihistamine used for allergic rhinitis, urticaria, pruritus, and related allergic symptoms. It is available in several markets as tablets, syrup, and, historically, extended-release formulations.

Dexchlorpheniramine is the dextrorotatory isomer of chlorpheniramine. It has antihistaminic and anticholinergic effects and can cause drowsiness, impaired alertness, dry mouth, and urinary retention. The FDA labeling for dexchlorpheniramine products identifies these central nervous system and anticholinergic risks.[1]

Item	Polaramine profile
Active ingredient	Dexchlorpheniramine maleate
Drug class	First-generation H1 antihistamine
Common strength	2 mg immediate-release tablet
Other dosage forms	Syrup and historical extended-release products
Primary uses	Allergic rhinitis, urticaria, pruritus
Administration	Oral
Regulatory category	Prescription or nonprescription, depending on country
Principal commercial risk	Generic substitution and competition from newer antihistamines

When does Polaramine lose exclusivity?

Polaramine lost meaningful market exclusivity decades ago. Dexchlorpheniramine is an old small-molecule active ingredient, and the relevant composition and formulation patents are no longer a material barrier to generic entry in the United States, Europe, Australia, Brazil, or other mature pharmaceutical markets.

The commercial distinction is between patent expiry and brand survival. Polaramine can remain on the market after patent expiry because pharmacies, physicians, and consumers may continue to recognize the brand. That residual value does not create legally protected exclusivity.

Patent status and expiration

A current, globally consolidated patent family protecting the basic dexchlorpheniramine molecule or the original Polaramine product is not identifiable as an active barrier. Historical patents covering the active ingredient and early formulations would have expired many years ago under the patent terms applicable when they were filed.

Patent category	Current commercial relevance
Dexchlorpheniramine composition patents	Expired
Original tablet formulations	Expired or no longer commercially material
Historical extended-release claims	Expired or formulation-specific
New-use patents	No major active estate identified
Manufacturing patents	Potentially relevant to an individual supplier, but not a barrier to ordinary generic production
Trademark rights	Potentially active by country and owner

Trademark protection remains more relevant than patent protection. The name Polaramine may be registered by different entities in different jurisdictions, and ownership can change through local transfers, licensing, or portfolio transactions.

What patents protect Polaramine?

No active foundational patent estate appears to protect Polaramine as a global product. The relevant IP stack is likely limited to trademarks, local regulatory registrations, packaging, and any supplier-specific manufacturing know-how.

Formulation patents

The original immediate-release tablet does not present a significant formulation barrier. Dexchlorpheniramine maleate is a conventional oral dosage form with well-established manufacturing methods.

Historical sustained-release products, including formulations marketed under extended-release or repeat-action branding, could have been covered by formulation patents or proprietary technologies. Those rights are not expected to remain enforceable for current commercial planning. A generic applicant would still need to address formulation performance, bioequivalence, stability, and labeling requirements.

Method-of-use patents

No commercially important active method-of-use patent estate has been identified for the conventional allergy indications associated with Polaramine. The indications are established and broad. A new patent could theoretically cover a narrow formulation, dosing regimen, or combination product, but that would not restore exclusivity to the legacy Polaramine brand.

What is the FDA regulatory status of Polaramine?

Dexchlorpheniramine is an FDA-recognized antihistamine active ingredient, but the regulatory status of the Polaramine brand itself depends on the specific U.S. product and sponsor. U.S. commercial availability has historically been less consistent than in markets where Polaramine remains an established branded product.

FDA approval does not equal current commercial distribution. A product can retain an approved application while being listed as discontinued, unavailable, or marketed by a different sponsor. Drugs@FDA, FDA labeling records, DailyMed, and the Orange Book must be reviewed at the product and application level.[1-3]

What is the Orange Book status of Polaramine?

The Orange Book is relevant only to approved U.S. drug products and their listed patents and exclusivity. A legacy dexchlorpheniramine product with no current Orange Book patent listing would have no listed patent blocking an ANDA applicant.

The practical Orange Book assessment is:

Question	Assessment
Active ingredient patent	No meaningful active protection identified
Listed formulation patent	No major current barrier identified
Listed method-of-use patent	No major current barrier identified
Paragraph IV exposure	Low in strategic importance because the product is mature
ANDA competition	Legally feasible, subject to current product availability and reference-product requirements

Which companies are challenging Polaramine?

Polaramine is not a major current Paragraph IV litigation target. The product is too mature and commercially fragmented to support the type of high-value patent challenge seen with blockbuster products.

Generic competition is more likely to arise through:

• Dexchlorpheniramine maleate tablets and oral solutions
• Private-label pharmacy products
• Local branded generics
• Combination cold and allergy products
• Substitution by chlorpheniramine, brompheniramine, cetirizine, loratadine, or fexofenadine

The absence of a prominent Paragraph IV campaign does not mean the product is protected. It reflects the limited revenue available from challenging a legacy antihistamine.

What patent litigation affects Polaramine?

No major current U.S. patent litigation involving Polaramine or dexchlorpheniramine has been identified as a material market event. Litigation risk is more likely to involve trademark ownership, distribution rights, product quality, advertising, or local registration disputes than compound patents.

Potential legal issues include:

1. Unauthorized use of the Polaramine trademark.
2. Disputes over local marketing authorization ownership.
3. Parallel-import and distributor rights.
4. Product-liability claims involving sedation or impaired driving.
5. Regulatory action involving labeling, packaging, or promotional claims.

There is no evident settlement agreement comparable to the confidential or public settlements associated with major branded prescription products.

How strong is the Polaramine patent estate?

The patent estate is weak for commercial purposes. A simplified assessment is:

Dimension	Rating	Reason
Composition patent protection	Very low	Old active ingredient
Formulation protection	Low	Conventional oral products; historical rights expired
Method-of-use protection	Very low	Established indications
Manufacturing protection	Low to moderate	Supplier-specific know-how may exist
Trademark protection	Moderate	Depends on country and registered owner
Regulatory exclusivity	None of material significance	Product is mature
Pricing protection	Very low	Generic and therapeutic substitution

The defensible asset is therefore the brand and channel position, not the molecule.

How does Polaramine compare with competing antihistamines?

Polaramine competes against both older sedating antihistamines and newer second-generation products.

Product	Active ingredient	Generation	Sedation risk	Commercial position
Polaramine	Dexchlorpheniramine	First	Relatively high	Mature branded or generic product
Chlor-Trimeton-type products	Chlorpheniramine	First	Moderate to high	Low-cost legacy competitor
Brompheniramine products	Brompheniramine	First	Moderate	Combination and allergy products
Zyrtec-type products	Cetirizine	Second	Lower, but possible	Strong OTC and generic competitor
Claritin-type products	Loratadine	Second	Low	Broad OTC penetration
Allegra-type products	Fexofenadine	Second	Low	Premium OTC and generic positioning

Newer antihistamines generally offer better convenience and lower sedation. That limits Polaramine’s ability to grow outside price-sensitive or locally established markets.

What is the competitive landscape?

Competition is fragmented and usually local. Relevant competitors include:

• Generic dexchlorpheniramine suppliers
• Generic chlorpheniramine manufacturers
• OTC antihistamine brands
• Local branded-generic companies
• Combination cough, cold, and allergy products
• Pharmacy private labels

The most important competitive variable is channel placement. A supplier with a low-cost generic can capture volume without investing in a new clinical profile. A brand owner can retain a premium only where Polaramine has strong physician or consumer recognition.

What is the financial trajectory for Polaramine?

Polaramine’s financial trajectory is consistent with a late-life pharmaceutical product:

1. Initial branded growth after launch.
2. Loss of patent protection and generic entry.
3. Declining average selling prices.
4. Market fragmentation across local licensees and generic suppliers.
5. Stabilization as a low-cost, mature product in selected countries.
6. Possible discontinuation where manufacturing, pharmacovigilance, or distribution costs exceed revenue.

Standalone revenue is not disclosed in the public reporting of major pharmaceutical companies. Polaramine is generally too small to receive separate reporting treatment. Revenue, when generated, is likely included within broader allergy, consumer health, or established-products categories.

Revenue exposure

The product’s revenue exposure is likely concentrated in:

• Countries where Polaramine retains strong brand recognition
• Prescription markets with established local registration
• Pharmacies serving consumers seeking low-cost sedating antihistamines
• Syrup and pediatric segments, where local labeling permits use
• Markets with limited penetration of newer antihistamines

Revenue is constrained by low price, substitution, and limited differentiation. A brand owner may still earn attractive gross margins if the product is manufactured at scale and sold through an established local network. Absolute revenue potential remains limited.

Financial drivers

Driver	Effect on Polaramine
Generic entry	Reduces price and volume share
OTC conversion	Can expand access but increases competition
Brand recognition	Supports premium pricing in selected markets
Manufacturing scale	Critical because unit prices are low
Regulatory maintenance	Can reduce profitability in small markets
Newer antihistamines	Erodes physician and consumer preference
Supply interruptions	Can shift demand to generic substitutes
Trademark strength	Supports local brand continuity

What generic launch risks exist for Polaramine?

Generic launch risk is high from a legal perspective and moderate from a commercial perspective.

A generic manufacturer would face no meaningful composition patent barrier, but commercial success would depend on reference-product availability, local regulatory requirements, and market size. In the United States, the principal challenge may be identifying a currently marketed reference product and establishing the appropriate regulatory pathway rather than overcoming patent litigation.

Generic launch scenarios

Scenario	Likely outcome
Immediate-release tablet launch	Low regulatory and technical complexity
Oral solution launch	Moderate complexity due to stability, taste, excipients, and pediatric labeling
Extended-release launch	Higher technical complexity and potential bioequivalence burden
Private-label launch	Low brand investment; price-led competition
Combination product launch	Greater commercial differentiation but more regulatory work
Branded-generic launch	Potentially stronger margins in markets with local brand loyalty

The most credible launch strategy is a low-cost immediate-release generic supported by established distribution. An extended-release product could offer differentiation, but the addressable market may not justify development costs.

What manufacturing and intellectual-property barriers affect Polaramine?

Manufacturing barriers are limited. Dexchlorpheniramine maleate is a conventional small molecule with established supply chains and standard oral dosage-form technology.

Operational risks include:

• Active pharmaceutical ingredient supplier qualification
• Impurity and assay control
• Tablet uniformity
• Stability in hot and humid climates
• Syrup preservative performance
• Packaging compliance
• Country-specific pharmacovigilance
• Sedation and driving warnings
• Continuity of supply for low-volume markets

These are execution barriers rather than defensible IP barriers. A manufacturer with an existing antihistamine portfolio can likely add dexchlorpheniramine with limited incremental development expense.

What licensing deals involve Polaramine?

No major recent global licensing transaction centered on Polaramine has been publicly disclosed. Commercial rights have historically been managed through country-specific marketing authorizations, distributors, local affiliates, or portfolio transfers.

Any transaction involving Polaramine is more likely to be:

• A local trademark license
• A product-rights transfer
• A contract manufacturing arrangement
• A distribution agreement
• A broader established-products portfolio transaction

The absence of a public global deal is consistent with the product’s limited revenue scale and fragmented ownership.

What geographic markets matter most for Polaramine?

Polaramine’s economic value is geographic rather than global. The brand has appeared in multiple international markets, but product status, sponsor, dosage forms, and prescription classification vary by country.

Geographic coverage

Region	Commercial assessment
United States	Mature dexchlorpheniramine market; brand continuity less certain
Europe	Country-specific presence; strong competition from newer antihistamines
Australia and New Zealand	Legacy antihistamine demand, subject to local registration and supply
Latin America	Brand recognition can remain meaningful; local ownership is important
Asia	Market access depends on national registrations and local distributors
Middle East and Africa	Established brands may coexist with imported generics

Global revenue cannot be calculated by adding nominal brand sales across countries because ownership and product status differ. Local sales may be reported under affiliate or distributor names rather than Polaramine.

What is the likely future of Polaramine?

Polaramine is likely to remain a niche, mature antihistamine rather than return to growth. The most probable trajectory is stable-to-declining volume with periodic market exits, SKU rationalization, and substitution by newer antihistamines.

Upside opportunities are limited to:

• Strong local trademark equity
• Cost-efficient generic or branded-generic supply
• Pediatric syrup availability
• Combination products
• Expansion in price-sensitive markets
• Improved distribution in countries where the brand remains recognized

The principal downside risks are generic substitution, supply interruptions, product discontinuations, and continued migration toward nonsedating antihistamines.

Key Takeaways

• Polaramine contains dexchlorpheniramine maleate, an old first-generation antihistamine.
• The product has no meaningful active global patent moat.
• Patent litigation and Paragraph IV activity are not major current risks.
• Trademark rights and local regulatory registrations are more important than patents.
• Standalone global revenue is not publicly disclosed.
• Financial performance is likely mature, fragmented, and low growth.
• Generic competition is legally feasible and commercially persistent.
• Newer antihistamines such as cetirizine, loratadine, and fexofenadine limit pricing power.
• The strongest commercial positions are likely in selected local markets with established brand recognition.
• Future value depends on efficient manufacturing, distribution, and trademark management.

FAQs about Polaramine market dynamics

Is Polaramine still patented?

No material active patent protection for the original dexchlorpheniramine product has been identified. The relevant protection expired many years ago.

Is Polaramine available over the counter?

The classification varies by country. It is prescription-only in some markets and available without prescription in others.

Can a generic manufacturer launch dexchlorpheniramine?

Yes. A manufacturer can generally pursue a conventional generic pathway, subject to the applicable national reference-product, bioequivalence, quality, and labeling requirements.

Does Polaramine have biosimilar competition?

No. Polaramine is a chemically synthesized small molecule, not a biologic. The relevant competition is generic substitution, not biosimilar competition.

Is Polaramine a high-value licensing asset?

Generally no. Its value is likely limited to local brand rights, distribution, and established regulatory registrations rather than global exclusivity or high-growth revenue.

References

1. U.S. Food and Drug Administration. (n.d.). Dexchlorpheniramine maleate prescribing information. FDA labeling database.
2. National Library of Medicine. (n.d.). DailyMed: Dexchlorpheniramine maleate drug labels. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
4. National Center for Biotechnology Information. (2024). Dexchlorpheniramine: PubChem compound summary. PubChem.
5. U.S. Food and Drug Administration. (2018). Drug approval package and labeling resources. Drugs@FDA.